Literature DB >> 12562112

The epidemiology of anxiety disorders: prevalence and societal costs.

Jean-Pierre Lépine1.   

Abstract

Anxiety disorders are the most prevalent of psychiatric disorders, yet less than 30% of individuals who suffer from anxiety disorders seek treatment. Prevalence of anxiety disorders is difficult to pinpoint since even small changes in diagnostic criteria, interview tools, or study methodology affect results. Analyses of the largest prevalence studies of psychiatric illnesses in the United States find that anxiety disorders afflict 15.7 million people in the United States each year, and 30 million people in the United States at some point in their lives. Currently, the European Study of Epidemiology of Mental Disorders and the World Health Organization World Mental Health 2000 studies are underway. These studies, which share a similar methodology, will facilitate future worldwide comparisons of the prevalence of anxiety disorders. Anxiety disorders impose high individual and social burden, tend to be chronic, and can be as disabling as somatic disorders. Compared with those who have other psychiatric disorders, people with anxiety disorders are high care utilizers who present to general practitioners more frequently than to psychiatric professionals, placing a strain upon the health care system. The economic costs of anxiety disorders include psychiatric, nonpsychiatric, and emergency care; hospitalization; prescription drugs; reduced productivity; absenteeism from work; and suicide.

Entities:  

Mesh:

Year:  2002        PMID: 12562112

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  61 in total

1.  Impairment and functioning in a sample of primary care patients with generalized anxiety disorder: results from the primary care anxiety project.

Authors:  Risa B Weisberg; Courtney Beard; Maria E Pagano; Kristin M Maki; Larry Culpepper; Martin B Keller
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 2.  Familial risk factors in social anxiety disorder: calling for a family-oriented approach for targeted prevention and early intervention.

Authors:  Susanne Knappe; Katja Beesdo-Baum; Hans-Ulrich Wittchen
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-10-06       Impact factor: 4.785

3.  Depression, anxiety, and quality of life in a large cohort of patients with rheumatic diseases: common, yet undertreated.

Authors:  Panagiota Anyfanti; Eleni Gavriilaki; Athina Pyrpasopoulou; George Triantafyllou; Areti Triantafyllou; Sofia Chatzimichailidou; Eugenia Gkaliagkousi; Spyros Aslanidis; Stella Douma
Journal:  Clin Rheumatol       Date:  2014-05-25       Impact factor: 2.980

Review 4.  Acupuncture for Treating Anxiety and Depression in Women: A Clinical Systematic Review.

Authors:  David P Sniezek; Imran J Siddiqui
Journal:  Med Acupunct       Date:  2013-06

5.  Mental health service use and treatment adequacy for anxiety disorders in Canada.

Authors:  Pasquale Roberge; Louise Fournier; Arnaud Duhoux; Cat Tuong Nguyen; Mirrian Smolders
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-03-09       Impact factor: 4.328

6.  The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Lenard Adler; Russell Barkley; Joseph Biederman; C Keith Conners; Olga Demler; Stephen V Faraone; Laurence L Greenhill; Mary J Howes; Kristina Secnik; Thomas Spencer; T Bedirhan Ustun; Ellen E Walters; Alan M Zaslavsky
Journal:  Am J Psychiatry       Date:  2006-04       Impact factor: 18.112

7.  Clinical and subthreshold panic disorder.

Authors:  Alexander Bystritsky; Lauren Kerwin; Noosha Niv; Jaime L Natoli; Natalie Abrahami; Ruth Klap; Kenneth Wells; Alexander S Young
Journal:  Depress Anxiety       Date:  2010-04       Impact factor: 6.505

Review 8.  Oxidative stress and anxiety: relationship and cellular pathways.

Authors:  Jaouad Bouayed; Hassan Rammal; Rachid Soulimani
Journal:  Oxid Med Cell Longev       Date:  2009 Apr-Jun       Impact factor: 6.543

9.  Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder.

Authors:  C François; S A Montgomery; N Despiegel; S Aballéa; J Roïz; P Auquier
Journal:  Int J Clin Pract       Date:  2008-08-28       Impact factor: 2.503

10.  Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974.

Authors:  Kieran Cooley; Orest Szczurko; Dan Perri; Edward J Mills; Bob Bernhardt; Qi Zhou; Dugald Seely
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.